Raymond James Financial
ZNTL icon

Raymond James Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Raymond James Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
22,785
-110
-0.5% -$439 ﹤0.01% 5162
2026
Q1 		$53.6K Buy
22,895
+3,000
+15% +$7.75K ﹤0.01% 5119
2025
Q4 		$26.9K Sell
19,895
-700
-3% -$1.02K ﹤0.01% 5065
2025
Q3 		$31.1K Hold
20,595
– – ﹤0.01% 4871
2025
Q2 		$23.9K Sell
20,595
-1,670
-8% -$2.2K ﹤0.01% 5528
2025
Q1 		$35.4K Sell
22,265
-175
-0.8% -$377 ﹤0.01% 4669
2024
Q4 		$68K Buy
+22,440
New +$73.5K ﹤0.01% 4568

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Raymond James Financial's ZNTL Position: Q2 2026 in Review

Raymond James Financial reduced its Zentalis Pharmaceuticals (ZNTL) stake by 0.48% in Q2 2026, selling an estimated $439 and leaving 22,785 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #5162.

Raymond James Financial first reported a position in ZNTL in Q4 2024 and has held it in 7 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Raymond James Financial held 22,785 shares of Zentalis Pharmaceuticals worth $111K as of Q2 2026.
  • Raymond James Financial sold 110 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $439.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5162 holding.
  • Raymond James Financial first reported a position in Zentalis Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.